Wockhardt Limited (WOCKPHARMA) launches Wockhardt Antibiotic Academy to tackle antimicrobial resistance and educate healthcare professionals.
Wockhardt Limited (WOCKPHARMA) reports Q1 FY27 results with a PAT of Rs. 107 Cr and revenue up 26% compared to previous year.
Wockhardt Limited (NSE: WOCKPHARMA) shows pressure after breakout, down 5% intraday at ₹1908.0. The stock has already cleared 6M resistance but faces profit-.
Wockhardt Limited (WOCKPHARMA) stock breaks out, gaining 5% intraday to ₹2018.0, clearing its 6M resistance trendline.
Wockhardt Limited (WOCKPHARMA) showcases innovation, performance, and growth at its June 2026 investor conference.
Wockhardt Limited (WOCKPHARMA) receives U.S. FDA approval for ZAYNICH™, a novel antibiotic for treating complicated urinary tract infections.
Wockhardt Limited (WOCKPHARMA) receives CDSCO approval for Zaynich® antibiotic for treating complicated urinary tract infections.
Wockhardt Limited reports strong FY 26 financials with Rs. 238 Cr profit before tax, marking significant growth in revenue and EBITDA.